Genome & Company (KOSDAQ:314130)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,990.00
-30.00 (-0.99%)
At close: Jul 9, 2025, 3:30 PM KST

Genome & Company Revenue

Genome & Company had revenue of 6.35B KRW in the quarter ending March 31, 2025, with 49.11% growth. This brings the company's revenue in the last twelve months to 29.84B, up 86.35% year-over-year. In the year 2024, Genome & Company had annual revenue of 27.74B with 94.07% growth.

Revenue (ttm)
29.84B
Revenue Growth
+86.35%
P/S Ratio
3.04
Revenue / Employee
304.46M
Employees
98
Market Cap
90.61B

Revenue Chart

Revenue History

Fiscal Year End Revenue Change Growth
Dec 31, 2024 27.74B 13.45B 94.07%
Dec 31, 2023 14.30B 211.39M 1.50%
Dec 31, 2022 14.08B 13.63B 3,021.27%
Dec 31, 2021 451.25M 300.66M 199.67%
Dec 31, 2020 150.58M 104.75M 228.54%
Dec 31, 2019 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Samsung Electronics 308.10T
SK hynix 71.40T
Samsung Biologics 4,898.69B
LG Energy Solution 25.76T
Hyundai Motor Company 178.98T
KB Financial Group 14.93T
Celltrion 3,662.23B
Kia Corporation 109.25T
Revenue Rankings